China Drug Role Splits Biotech, FDA Names Acting Heads
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- China’s expanding role in global drug development is creating a sharp divide among U.S. biotech executives over strategic reliance.
- U.S. biotech industry executives publicly debate whether dependence on Chinese partners is a competitive necessity or a national‑security risk.
- FDA has appointed new acting directors for both CBER and CDER as part of a broader agency restructuring.
Why it matters: FDA’s appointment of two new acting directors for CBER and CDER reshapes agency leadership, directly influencing biotech firms that depend on timely drug approvals and investor confidence.
